Rapisep: A plasma separator for at-home micronutrient testing
RapiSep is an affordable, easy-to-use device for rapid plasma separation, enabling real-time micronutrient monitoring at home. It facilitates accurate health tracking with results comparable to laboratory tests, promoting proactive health management.
Overview
RapiSep is a groundbreaking device designed to transform micronutrient monitoring by enabling accurate and convenient blood plasma separation at home. This thumb-sized device is user-friendly, requiring only three simple actions: sip, tap, and cap. It spontaneously loads 35 μL of blood and separates 12 μL of plasma in just one minute, offering users an efficient and cost-effective solution. The device is poised to make routine health tracking accessible, with each unit costing less than $1. By leveraging advanced detection techniques and collaborating with assay developers, RapiSep aims to deliver diagnostic results with reliability comparable to those obtained from traditional laboratory tests.
Technical specifications
- Device usability: Simple operations include sip, tap, and cap
- Blood and plasma volumes: 35 μL of blood, separating 12 μL of plasma
- Separation time: 1 minute
- Cost-effectiveness: Each device costs less than $1
- Integration: Designed for seamless integration with downstream testing devices for at-home micronutrient measurement
Technology readiness level
The current TRL of RapiSep is 5, indicating it is in the validation and prototyping phase. The device's development plan includes further validation of its plasma separation reliability and accuracy compared to standard laboratory methods. Future validation efforts will focus on verifying measurement accuracy for micronutrients and refining the interface for multiplexing detection. RapiSep is expected to enter the market as part of an over-the-counter kit, in collaboration with device and kit manufacturers.
About microFAST Dx
microFAST Dx is a rapid diagnostics company that specializes in upstream sample collection and processing technologies designed to facilitate decentralized diagnostics. The company develops microscale sample processing devices, such as its RapiSep plasma separation technology, which simplifies sample preparation workflows by converting blood to plasma. These devices are intended to function either as standalone tools or as interfaces for downstream analysis, aiming to bridge the gap between initial sample collection and final testing.
By focusing on user-friendly, portable solutions, microFAST Dx seeks to empower in vitro diagnostics (IVD) developers to offer blood testing that can be performed by individuals with minimal training in various settings, including at home or at point-of-care locations. The company's technology is designed to expand the accessibility of rapid blood tests for applications such as health and wellness monitoring, chronic disease management, and acute infection testing. microFAST Dx operates as a wholly owned entity of Zymeron Corporation.
delivered to your inbox.